Despite the increased cancer risk for BRCA1 or BRCA2-carrying males, national guidelines on genetic testing and cancer screening have been slower to emerge for males, and national guidelines are now beginning to include more specific measures for males. With less public awareness of the risk for ...
Purpose: We assessed the cost-effectiveness of mammography screening for women under the age of 50, from breast cancer families without proven BRCA1./BRCA2 mutations, because current criteria for screening healthy women from breast cancer families are not evidence-based. Methods: We did simulation ...
检索时限起始于1990年1月,截至2023年8月,英文文献检索词主要包括BRCA1/2、hereditary breast cancer、hereditary ovarian cancer、germline mutation、screening test、population screening、BRCAscreening、cancer risk assessment、cancer susceptib...
Paluch‑Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F and Senkus E; ESMO Guidelines Committee: Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer...
[4]Lang G T, Shi J X, Hu X, et al. The spectrum of BRCA mutations and characteristics of BRCA‐associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next‐generation sequencing[J]...
Comment & Response Proposed Shift in Screening for Breast Cancer Beverly Levine, PhD; Karen Steinberg, PhD JAMA Comment & Response Proposed Shift in Screening for Breast Cancer Mary-Claire King, PhD; Amnon Lahad, MD, MPH; Ephrat Levy-Lahad, MD JAMA The...
From the set-up of a screening program of breast cancer patients to the identification of the first BRCA mutation in the DR Congo From the set-up of a screening program of breast cancer patients to the identification of the first BRCA mutation in the DR Congo. BMC Public Health,... GL ...
Hormonal shifts that occur during pregnancy, the postpartum period, and breastfeeding result in changes to the breasts that may further complicate the sensitivity and specificity of screening modalities. We explore the safety and efficacy of available breast cancer screening modalities, including clinical...
breast and ovarian cancers in female carriers, and knowledge ofBRCA1/2PVs informs established cancer screening and options for risk reduction. While risks to male carriers ofBRCA1/2PVs are less characterized, there is convincing evidence of increased risk for prostate cancer, pancreatic cancer, and...
[3] Paluch-Shimon S, Cardoso F, Sessa C, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening[J]. Ann Oncol,2016,(suppl 5):v103-v110. ...